Eli Lilly released TRIUMPH-1 topline on May 21, the pivotal Phase 3 trial of retatrutide ↗ in obesity. Across 2,339 adults with obesity or overweight plus at least one weight-related comorbidity, without type 2 diabetes, the 12 mg dose produced a mean body-weight loss of 28.3 percent at 80 weeks. The 9 mg dose came in at 25.9 percent, 4 mg at 19.0 percent, and placebo at 2.2 percent. All three doses met the primary and key secondary endpoints. The threshold breakdown matters more than the mean: on 12 mg, 45.3 percent of patients reached at least 30 percent loss. That is the threshold the field has historically reserved for bariatric surgery.
The discontinuation rate at the top dose was 11.3 percent due to adverse events, versus 4.9 percent on placebo. The middle and low doses ran 6.9 percent and 4.1 percent. Most events were gastrointestinal (nausea, diarrhea, constipation, vomiting), concentrated during dose escalation, mild to moderate, decreasing over time. The 12 mg dropout rate sits roughly double Wegovy ↗ 2.4 mg in STEP 1 (around 6.5 percent) and tirzepatide ↗ 15 mg in SURMOUNT-1 (around 7 percent). For the prescriber, the tolerability gap is the trade-off against the efficacy gap.
What the numbers mean in plain terms
A 28.3 percent mean body-weight loss on a 240-pound patient is about 68 pounds. The 12 mg arm averaged 70.3 pounds lost. In a pre-specified 104-week extension in patients with baseline BMI of 35 or higher who tolerated their assigned dose, the mean reached 30.3 percent, or 85.0 pounds. The continuous-loss pattern out to two years matters because the typical concern with this drug class is plateau and regain. The extension data suggest that, in patients who clear the tolerability hurdle, weight keeps coming off through year two.
The threshold breakdown is where the bariatric comparison lands. At 12 mg, 62.5 percent of patients reached at least 25 percent loss, 45.3 percent reached at least 30 percent, and 27.2 percent reached at least 35 percent. The corresponding placebo numbers were 2.2 percent, 0.5 percent, and 0.3 percent. Wegovy 2.4 mg in STEP 1 produced a mean of about 15 percent loss; tirzepatide 15 mg in SURMOUNT-1 produced about 21 percent. Retatrutide is on a different vertical.
The ALT signal came back, briefly
The other thing that landed alongside the efficacy was the hepatic-enzyme story. TRIUMPH-4 in December 2025 had flagged transient ALT elevations on retatrutide, and the field was watching for that signal in the pivotal. It reappeared, again as transient ALT increases concentrated on the 9 mg and 12 mg arms, normalizing by week 24. Liver fat dropped more than 80 percent on the 8 mg to 12 mg dosing in a substudy that Lilly read out alongside the safety data. The company's reading is that the transient transaminitis reflects hepatic triglyceride mobilization (the liver dumping its stored fat back into circulation as it shrinks), not hepatotoxicity. The mechanistic argument is plausible. The number to watch in TRIUMPH-2 and TRIUMPH-3 is whether the same transient pattern holds in comorbidity-enriched populations.
What is needed for the label
TRIUMPH-1 alone is not the NDA package. Lilly's planned regulatory submission requires the readouts of TRIUMPH-2 (retatrutide in obesity plus type 2 diabetes) and TRIUMPH-3 (retatrutide in obesity plus established cardiovascular disease), both expected later in 2026. Full TRIUMPH-1 data will be presented at the American Diabetes Association meeting in New Orleans, June 5 to 8, with the topline already in today's peptide news digest ↗. The TRANSCEND T2D1 readout already cleared retatrutide's first Phase 3 in type 2 diabetes (covered in our May 3 piece ↗). TRIUMPH-1 is the obesity matching pair to that.
Platform note
Retatrutide is the first triple-receptor agonist to clear a pivotal Phase 3, hitting GIP, GLP-1, and glucagon. The card sits on the GLP-1R target page ↗ alongside its dual and single-receptor cousins. The mechanistic difference that matters here is the glucagon arm: agonism at the glucagon receptor raises energy expenditure and mobilizes hepatic fat, which is the same mechanism behind both the over-80-percent liver-fat reduction and the transient ALT bumps. That dual-edge behavior is intrinsic to the receptor architecture, not a formulation problem. The peptide design space for triple agonists is still small. Boehringer Ingelheim's BI 3034701, mentioned in the April 28 digest ↗, is the closest competitor in this lane and is several years behind. For the obesity prescribing class, retatrutide is now the molecule that defines the upper edge of what a peptide drug can deliver without surgery. The tolerability tax keeps the GLP-1 monotherapy market relevant for patients who cannot stomach what the triple agonist asks of them.